Journal of thrombosis and haemostasis : JTH · 2006
Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lindqvist P G, Svensson P, Dahlbäck B
Аннотация
BACKGROUND: Activated protein C (APC) resistance with or without factor V Leiden (FVL) is a major risk factor for venous thromboembolism. Many previous pregnancy studies have been focused on APC resistance caused by FVL. Very few have investigated APC resistance in the absence of FVL (APCR(FVL-)).
MATERIAL AND METHODS: In a prospective study of 2480 unselected gravidae, blood was drawn in early pregnancy (mean = 12 weeks of gestation). APC resistance was analyzed by an APTT-based method (Coatest) APC-resistance) and the presence of FVL was determined by PCR. The APCR(FVL-) group had similar mean APC resistance ratio as the heterozygous carriers of FVL. The analyses were carried out no earlier than 3 months after delivery when all data were recorded. Small-for-gestational age (SGA) was used as a proxy for intrauterine growth restriction.
RESULTS: When compared with the control group, women with APCR(FVL-) had no increased risk of SGA, pre-eclampsia, first trimester fetal loss or venous thromboembolism. However, they had an increased risk of second trimester fetal loss (7.3% vs. 2.7%, P = 0.01), and a tendency of being overweight (17.3% vs. 12.6%, P = 0.19) and of delivering extremely preterm (2.8% vs. 1.0%, P = 0.11).
CONCLUSION: Women with APC resistance not caused by FVL were not at increased risk for SGA, pre-eclampsia, first trimester fetal loss, or abnormal blood loss. However, they showed an increased prevalence of second trimester fetal loss.
MATERIAL AND METHODS: In a prospective study of 2480 unselected gravidae, blood was drawn in early pregnancy (mean = 12 weeks of gestation). APC resistance was analyzed by an APTT-based method (Coatest) APC-resistance) and the presence of FVL was determined by PCR. The APCR(FVL-) group had similar mean APC resistance ratio as the heterozygous carriers of FVL. The analyses were carried out no earlier than 3 months after delivery when all data were recorded. Small-for-gestational age (SGA) was used as a proxy for intrauterine growth restriction.
RESULTS: When compared with the control group, women with APCR(FVL-) had no increased risk of SGA, pre-eclampsia, first trimester fetal loss or venous thromboembolism. However, they had an increased risk of second trimester fetal loss (7.3% vs. 2.7%, P = 0.01), and a tendency of being overweight (17.3% vs. 12.6%, P = 0.19) and of delivering extremely preterm (2.8% vs. 1.0%, P = 0.11).
CONCLUSION: Women with APC resistance not caused by FVL were not at increased risk for SGA, pre-eclampsia, first trimester fetal loss, or abnormal blood loss. However, they showed an increased prevalence of second trimester fetal loss.